Trial Profile

Efficacy and Safety of Pasireotide Long Acting Release (LAR) in Combination With Weekly Pegvisomant in Previously Controlled Acromegaly Patients on Combination Treatment of Long-Acting Somatostatin Analogues and Weekly Pegvisomant

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 26 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 May 2020 Results (n=45) assessing relationship between the predictors and the hormonal and tumoral responses to long-acting pasireotide (PAS-LAR) therapy compared with responsiveness to first-generation somatostatin receptor ligands, published in the European Journal of Endocrinology.
18 Mar 2019 Results assessing T2-signal intensity and SST receptor expression in relation to the hormone and tumor response during PAS-LAR treatment presented at the 101st Annual Meeting of the Endocrine Society
12 Oct 2018 Results (n=59) of the extension study of 48 weeks ,published in the European Journal of Endocrinology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com